According to a report in Europe, a Paris court found that Medtrum’s latest insulin pumps infringe an Insulet (Nasdaq:PODD) patent.
JUVE Patent reported that earlier this month, the Judicial Court of Paris declared the infringement. The court found that Medtrum’s newest pump base and patch reservoir models violate the EP2438957B1 patent from Insulet.
In declaring the infringement, the court ordered Medtrum to recall its Nano TouchCare pumps sold in France. Patients already using the device received an exemption.
China-based Medtrum describes itself as “a company dedicated to simplifying the management of diabetes.” It develops and delivers medical devices including pumps and glucose monitors. Medtrum also aims to produce an artificial pancreas system.
Among its offerings are the EasyPatch, a tubeless pump controlled with a smartphone app. The TouchCare Nano CGM monitors glucose levels and sends data to a smart device. Medtrum’s TouchCare Nano insulin pump is, like the Insulet Omnipod platform, a tubeless, wearable patch pump. It integrates with the CGM and smart devices to form the TouchCare Nano hybrid closed-loop automated insulin delivery system.
Insulet’s infringed patent describes the device as one for delivering fluid to a patient. It features an exit port assembly, a reservoir, a plunger and a sensor, among several other details. The company filed the patent in 2001.
According to JUVE Patent, the win in France for Insulet follows a determination in Germany that Medtrum’s A7+ model infringes the same patent. A Düsseldorf court ordered Medtrum’s subsidiaries to cease and desist, render accounts, recall and destroy infringing products and pay damages for past infringement. The outlet reports no other legal proceedings between the companies.
